13
Participants
Start Date
December 31, 2009
Primary Completion Date
September 30, 2012
Study Completion Date
December 31, 2012
Erlotinib
Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
Temsirolimus
In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque
University of New Mexico Cancer Center, Albuquerque
Collaborators (1)
Genentech, Inc.
INDUSTRY
New Mexico Cancer Research Alliance
OTHER